Endoscopic submucosal dissection to remove large colorectal lesions was performed safely and successfully in an outpatient setting, based on data from more than 600 patients. The widespread adoption ...

A research team at Tohoku University, in collaboration with Denka Company Limited and U-A Corporation, has developed a ...

A prospective clinical trial from researchers in Japan shows magnetic-anchor-guided endoscopic submucosal dissection for large early gastric cancer to be a feasible and safe method in humans.

Olympus launched DualKnife J, an endoscopic submucosal dissection electrosurgical knife, May 31. The knife will be on display at Digestive Disease Week, June 2 to June 5 in Washington, D.C. Here’s ...

Endoscopic submucosal dissection (ESD) appeared effective for removing superficial gastric neoplasia and is therefore a viable option for patients in North America, a retrospective, multicenter study ...

World’s First Fully Robotic Procedure by a Gastroenterologist Completed using EndoQuest’s Endoluminal Surgical System in the PARADIGM Trial Dr. Norio Fukami of Mayo Clinic, Arizona is first ...

Additionally, the publication of clinical guidelines by leading gastroenterological societies in Western countries has legitimized the use of ESD for treating early-stage gastric, esophageal, and ...

EndoQuest Robotics has received FDA approval to proceed with the final enrollment phase of its pivotal Paradigm trial evaluating a robotic endoluminal system for gastrointestinal procedures. The ...

Endoscopic submucosal dissection (ESD) represents a significant advance in therapeutic endoscopy with the major advantage being the ability to achieve a higher en bloc resection rate for early stage ...

In a recent press release from Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today ...

Please provide your email address to receive an email when new articles are posted on . Bartel and colleagues assigned 3 mg budesonide orally twice a day for 8 weeks to 25 patients who underwent ...

Houston, TX, Sept. 25, 2025 (GLOBE NEWSWIRE) -- EndoQuest Robotics, Inc., a pioneering leader in endoluminal robotic surgical technology, today announced the completion of the first procedure ...